OptimizeRx Corporation provided financial guidance for the year 2022. For the period, the company is updating its full year financial outlook for 2022 and now expects net revenue of $62 million to $68 million, representing year-over-year growth of 1% to 11%, respectively, and gross margins to be between 59% and 62%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.29 USD | -1.74% | -6.69% | -21.10% |
05/06 | Transcript : OptimizeRx Corporation - Shareholder/Analyst Call | |
14/05 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.10% | 206M | |
+27.66% | 452B | |
+33.20% | 279B | |
+11.91% | 144B | |
+7.98% | 93.32B | |
+25.13% | 91.51B | |
+70.03% | 63.37B | |
+15.32% | 46.64B | |
+25.04% | 36.22B | |
-11.83% | 31.47B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Provides Financial Guidance for the Year 2022